Aurobindo Pharma gains ahead of US Food and Drug Administration (US FDA) target action date for Renvela generic. In an interview to CNBC-TV18, Amey Chalke, Research Analyst at HDFC Securities shared his readings and outlook on the stock.
first published: Jul 14, 2017 04:46 pm
A collection of the most-viewed Moneycontrol videos.
The Lawyer Renting in a 120-year-old building in South Mumbai | The Tenant
Nifty On Track To End Week Above 25,500 As Bank & Metal Stocks Lead Rebound| Closing Bell Live
Can Nifty Stage A Friday Fightback After Hitting 3-Week Low? Pine Labs IPO Opens | Opening Bell Live
Nifty Stays Below 25,600 Amid Expiry-Led Volatility; Grasim, Hindalco In Focus| Closing Bell Live
